Revenue Rises, Patient Activity Weakens, and Care Routes Shift

|13 min read
veterinarian discusses exam with client, her child and a small dog in the waiting room of an independent vet clinic.

Theme this week

Revenue rose, but visits, patients and product buying stayed weak. Deals and launches may change who runs services and approves orders, while a U.S. Food and Drug Administration (FDA) drug-site proposal may change who keeps records. This month, match sales dollars to patients and units, then check contract terms, who decides and where orders go.

Executive takeaways

  1. Compare revenue with visits, patient counts, and preventive product units this month. Together, the three datasets show revenue growth without matching growth in patient activity or preventive purchases. 1, 2, 3
  2. Review current VitalRADS service and data terms before the expected third-quarter close. Zoetis has agreed to buy VitalRADS, but terms for service, storage, support, and image export after closing remain unknown. 4
  3. Confirm who approves purchases across Bond Vet and Small Door within 30 days. The combined group has more than 55 clinics, while buying decisions may centralize before clinic workflows change. 5
  4. Track first and repeat orders for Royal Canin diets and the PetMeds-Rural King pharmacy each month. Both launches are live, but neither has reported order completion or repeat ordering. 6, 7
  5. Confirm who maintains registration and drug listing records for each manufacturing site before the September 11 comment deadline. The FDA proposal would let linked sites register together, but it is not yet final. 8

Signals

1. Practice revenue rises while patients and preventive purchases fall

OBSERVED

Animalytix reported revenue up 2.6% year to date through July 11, 2026 across about 3,000 practices. In a separate sample, it tracked product spending through June 30 at more than 32,000 practices and shelters. Practice purchase spending was down 3.8% for core and lifestyle vaccines and 2.2% for parasite control. 1

Vetsource used second-quarter data from more than 7,000 practices. Patients buying vaccines fell 8% for dogs and 3% for cats. Patients buying parasite control fell almost 11% for dogs and 2% for cats. The share of patients buying vaccines stayed stable. The canine share buying parasite control fell about 1%, while the feline share stayed stable. 2

The Veterinary Hospital Managers Association reported revenue up 2.7% and revenue per patient up 4.2%. Visits fell 0.6%. Active-patient and new-client counts also stayed below the prior year. 3

VIEWPOINT

The three sources cover different samples, periods and measures, so their figures should remain separate. Together, they show revenue growth without matching growth in patient counts or preventive purchases. The gap may reflect higher prices, more services per patient or a different service mix. Operators should review revenue, visits, patients, purchasing patients and units as separate measures.

CONFIDENCE

Moderate — three source datasets point in the same direction, but they cover different samples, periods and measures.

ACTIONS

Independent veterinary practices

  • Compare weekly revenue with visits, active patients and vaccine and parasite control units through August.
  • Review how many patients bought vaccines and parasite control before the next order cycle.

Corporate veterinary groups and clinic consolidators

  • Flag clinics where revenue rises while visits or preventive units fall this month.
  • Show price changes, types of services sold and patient activity separately in August network forecasts.

Distributors, e-retail and home delivery providers

  • Update vaccine and parasite control demand forecasts by account type before August replenishment.
  • Track vaccine and parasite control order changes by account each week through August.

Manufacturers and commercial operators

  • Check vaccine and parasite control forecasts against the number of patients buying products and units shipped this month.
  • Update account plans for customers with falling preventive orders before August planning.

↑ Back to top

2. Zoetis agrees to acquire VitalRADS for imaging services

OBSERVED

Zoetis agreed on July 14, 2026 to buy VitalRADS, which provides remote image review, mobile ultrasound, outpatient imaging and cloud image storage. VitalRADS reports more than 1,800 active customers and mobile ultrasound service to more than 200 clinics. 4

Zoetis expects the deal to close in the third quarter of 2026. Closing still depends on standard closing conditions and regulatory approval. The companies did not disclose financial terms. The deal is not complete, and Zoetis has not announced service, storage and support terms after closing. 4

VIEWPOINT

If the deal closes, Zoetis would add VitalRADS’ remote image review, mobile ultrasound and storage services to its diagnostics business. For clinics already using Zoetis diagnostics and VitalRADS, Zoetis could then handle more of the imaging process, from specialist review to report delivery and storage. Before the deal closes, VitalRADS customers should record fees, turnaround times, renewal terms, how images and reports enter clinic software and how staff download them.

CONFIDENCE

High — the Zoetis announcement confirms the agreement and closing window. Later integration and service terms remain unknown.

ACTIONS

Independent veterinary practices

  • Document current image-review time, fees and export rights before the expected third-quarter close.
  • Request written post-close service, storage and support terms before the next renewal.

Corporate veterinary groups and clinic consolidators

  • Map VitalRADS and Zoetis imaging use across clinics within 30 days.
  • Set network standards for image export, uptime and specialist response time before the expected close.

Distributors, e-retail and home delivery providers

  • Identify imaging accounts affected by the deal in internal sales and support records this month.
  • Confirm who will handle support for affected accounts before the expected close.

Manufacturers and commercial operators

  • List accounts likely to ask about imaging compatibility or data export before third-quarter sales planning.
  • Prepare evidence on compatibility, support response times and data export for imaging products this quarter.

↑ Back to top

3. Bond Vet and Small Door complete merger, combining more than 55 clinics

OBSERVED

Bond Vet and Small Door Veterinary finalized their merger on July 9, 2026. The combined company reports more than 55 clinics, more than 500,000 pets served, over 170 veterinarians and more than 1,000 team members. Its clinics span Northeast, Mid-Atlantic and Midwest markets. 5

Small Door co-founder Florent Peyre will lead the combined company as chief executive officer. Both brands will keep their names initially. The companies gave no timeline for a later branding change. Financial terms were not disclosed. 5

VIEWPOINT

The merger creates a larger multi-clinic veterinary group, but integration may move at different speeds. Procurement may centralize before brands, referral rules or clinic workflows are combined. Suppliers should confirm where buying decisions sit, while nearby practices should track changes in referrals and local services.

CONFIDENCE

High — the Bond Vet and Small Door Veterinary release confirms the completed merger, scale and near-term brand structure. Integration timing remains unknown.

ACTIONS

Independent veterinary practices

  • Map overlapping clinics and referral routes within 30 days.
  • Confirm referral contacts and intake rules at affected clinics through September.

Corporate veterinary groups and clinic consolidators

  • Map clinic overlap with the combined group by market this month.
  • Confirm which referral relationships may be affected in overlapping markets within 30 days.

Distributors, e-retail and home delivery providers

  • Confirm billing, delivery and procurement contacts for both brands this month.
  • Track order consolidation and support changes by clinic through September.

Manufacturers and commercial operators

  • Confirm internal account leads and the people making category decisions for both brands within 30 days.
  • Separate group-wide agreements from local clinic commitments before the next proposal.

↑ Back to top

4. Royal Canin launches three fresh therapeutic dog diets through clinics and veterinary pharmacies

OBSERVED

Royal Canin launched three fresh, cooked dog diets in the U.S. on July 14, 2026. One is low fat for digestive care. One uses a selected protein for food sensitivity. The third supports dogs with low appetite. 6

Participating veterinary clinics and online veterinary pharmacies can sell the diets. Royal Canin is providing training and product information to participating veterinary teams. 6

VIEWPOINT

The launch adds a fresh, cooked option to therapeutic nutrition sold through clinics and veterinary pharmacies. The commercial test is whether a clinic recommendation becomes a completed first order and reliable repeat delivery. Operators should measure that path before wider promotion.

CONFIDENCE

High — the Royal Canin release confirms the launch, products and sales routes. Uptake and repeat orders remain unreported.

ACTIONS

Independent veterinary practices

  • Confirm whether the clinic will order, store or arrange delivery before recommending the diets
  • Track first-order completion and repeat orders monthly after launch

Corporate veterinary groups and clinic consolidators

  • Set approved ordering and client follow-up steps within 30 days
  • Compare first orders and repeat orders across participating clinics each month

Distributors, e-retail and home delivery providers

  • Set stock and delivery rules before listing the diets
  • Track order accuracy and recurring-delivery continuity each week after launch

Manufacturers and commercial operators

  • List therapeutic diet categories that now compete with fresh, cooked products this quarter
  • Prepare sales-team answers on format, storage and delivery using approved evidence this month

↑ Back to top

5. PetMeds and Rural King launch a retailer-linked online pharmacy

OBSERVED

PetMeds and Rural King launched a co-branded online pharmacy on July 14, 2026. The service includes medicines, prescription food, parasite control products and other pet health products. Eligible medicines, preventatives and prescription are eligible for automatic repeat orders. 7

PetMeds provides the pharmacy platform, licensed pharmacists and online order processing. Customers can access the service through RuralKing.com or a co-branded site. Rural King reports more than 150 stores in 17 states. 7

VIEWPOINT

The co-branded pharmacy gives Rural King customers a prescription and repeat-order channel powered by PetMeds. It could add outside-pharmacy approval work for clinics and compete for repeat medicine and prescription-diet orders. Completed first orders will show initial use; repeat orders will show continued use.

CONFIDENCE

High — the PetMeds and Rural King release confirms the live service, assortment and route. Completion and repeat-order use remain unreported.

ACTIONS

Independent veterinary practices

  • Track prescription requests from the PetMeds and Rural King pharmacy each week, including approval time.
  • Update neutral staff talking points for outside-pharmacy requests before this month’s training.

Corporate veterinary groups and clinic consolidators

  • Measure outside-pharmacy requests and completed authorizations by region each week through September.
  • Standardize outside-pharmacy approval steps across exposed clinics within 30 days.

Distributors, e-retail and home delivery providers

  • Compare fill rates and authorization times in Rural King markets each month.
  • Compare repeat-order completion in Rural King markets with other markets through the third quarter.

Manufacturers and commercial operators

  • Map products available through the co-branded pharmacy this month.
  • Review channel and promotion approvals for listed products before the next campaign.

↑ Back to top

6. FDA proposes shared registration for distributed drug manufacturing

OBSERVED

The FDA proposed changes to drug-establishment registration and drug-listing requirements on July 13, 2026. The proposal covers companies that divide drug manufacturing across several sites and some foreign sites, including animal-drug sites.8

If finalized, one main site, called a hub, and linked units at other sites could register as one establishment. The proposal would also make clear which foreign sites must register. Comments close September 11, 2026. 8

VIEWPOINT

A shared registration could consolidate registration work across linked manufacturing sites. Clearer foreign-site rules could also change who maintains registration, drug-listing and update records. Manufacturers and importers should map those duties before September 11. Practices and distributors should wait for a final rule before changing buying procedures.

CONFIDENCE

High — FDA has issued the proposal and comment deadline. The final wording, effective date and operating requirements remain uncertain.

ACTIONS

Independent veterinary practices

  • Keep current medicine-buying procedures until FDA issues a final rule.
  • Record any supplier notices about registration changes this quarter.

Corporate veterinary groups and clinic consolidators

  • Ask suppliers which critical drugs use several or foreign manufacturing sites by September 11.
  • Record who owns registration updates for each identified drug this quarter.

Distributors, e-retail and home delivery providers

  • Map manufacturers, importers and registered sites for animal drugs made across several sites before September 11.
  • Confirm who maintains registration and drug-listing data for each import route this month.

Manufacturers and commercial operators

  • Check hub, unit, importer and foreign-site records against the proposal before September 11.
  • Prepare comments on unclear recordkeeping or update requirements before September 11.

↑ Back to top

Methodology and governance

This PULSE Edition covers developments posted or acted on from July 8 through July 15, 2026, using U.S. Eastern Time.

Observed statements are anchored to public sources and attributed subscriber reports cited below. Viewpoints are PETMETRIX assessments that interpret commercial implications for operators. Early watch items are early hypotheses. They are not yet strong enough for a full Signal, and they include what would confirm or rule out the pattern.

PETMETRIX PULSE commercial intelligence is provided for informational use and to support lawful, independent business decisions. It is not legal, clinical, reimbursement, accounting, or financial advice. Route legal, clinical, reimbursement, accounting, and financial decisions to qualified advisers. Respect for the veterinary-client-patient relationship is mandatory.

Terms of Service | Privacy Policy | Methodology and Data Disclaimer

Glossary

Active patient: A patient counted as current because the practice recorded a visit or transaction within a stated look-back period, often 12 or 18 months. The period should be stated because definitions vary.

Core vaccine: A vaccine recommended for all animals of a species unless a specific medical reason makes vaccination unsuitable.

Distributed drug manufacturing: A decentralized model in which equivalent production units at different locations make the same drugs under one management and one quality system.

Distributed manufacturing hub: A proposed FDA term for the main location of the quality unit that directs, monitors, and controls manufacturing across linked production units.

Distributed manufacturing unit: A proposed FDA term for a physical production unit located separately from the hub that makes or processes drugs and may be moved between locations.

Drug establishment registration: An FDA filing that identifies a site involved in making, repacking, or relabeling drugs. Registration does not mean FDA approval.

Drug listing: An FDA filing that identifies drugs made for commercial distribution and provides required product information. Listing does not mean FDA approval.

Fill rate: How often a supplier or distributor ships the full order on time.

Final rule: A regulation an agency has adopted and published. It normally states the legal text and the date it takes effect.

Lifestyle vaccine (noncore vaccine): An informal term for a noncore vaccine recommended for some animals based on lifestyle, location, and risk of exposure.

Observed: A statement anchored in an attributable source, for example a company announcement, regulator posting, publication, data release, or market report.

Outside-pharmacy authorization: A clinic approval or response step when a client asks for a prescription to be filled by an online or third-party pharmacy.

Remote image review (teleradiology): The electronic transfer of diagnostic images to a specialist who interprets and reports on them from another location.

Retailer-branded pharmacy service: A pet prescription service sold under a retailer’s brand and operated by a pharmacy partner.

Signal: A sourced market, company, product, policy, data, or behavior change with a clear commercial implication.

Therapeutic diet: A veterinary diet recommended for a specific health condition or clinical need.

Viewpoint: PETMETRIX interpretation of observed facts through a commercial lens.

References

  1. Animalytix. “Vet Watch® Insight Report - YTD Week 27, July 2026.” July 14, 2026. Subscriber email received by PETMETRIX July 14, 2026. https://www.vetwatch.com
  2. Vetsource. “Veterinary Practice Insights from Vetsource®.” The Fountain Report. July 10, 2026. Subscriber email received by PETMETRIX July 10, 2026. https://www.antelligence.com/the-fountain-report/
  3. Veterinary Hospital Managers Association. “VHMA Insiders’ Insights KPI Quarterly Commentary - July 2026.” July 8, 2026. https://www.vhma.org/blogs/vhma-admin/2026/07/08/insiders-insights-kpi-quarterly-commentary-july26
  4. Zoetis Inc. “Zoetis Announces Agreement to Acquire VitalRADS, Accelerating Diagnostic Capabilities.” July 14, 2026. https://news.zoetis.com/press-releases/press-release-details/2026/Zoetis-Announces-Agreement-to-Acquire-VitalRADS-Accelerating-Diagnostic-Capabilities/default.aspx
  5. Bond Vet and Small Door Veterinary. “Bond Vet and Small Door Veterinary Merge to Expand Access to Trusted Veterinary Care.” July 9, 2026. https://www.prnewswire.com/news-releases/bond-vet-and-small-door-veterinary-merge-to-expand-access-to-trusted-veterinary-care-302821175.html
  6. Royal Canin. “Royal Canin® Launches Its First Fresh Therapeutic Diet Portfolio Available Exclusively Through Veterinarians.” July 14, 2026. https://www.prnewswire.com/news-releases/royal-canin-launches-its-first-fresh-therapeutic-diet-portfolio-available-exclusively-through-veterinarians-302825457.html
  7. PetMed Express, Inc. “PetMeds and Rural King Expand Access to Pet Healthcare Through New Online Pharmacy Platform.” July 14, 2026. https://www.globenewswire.com/news-release/2026/07/14/3326792/0/en/PetMeds-and-Rural-King-Expand-Access-to-Pet-Healthcare-Through-New-Online-Pharmacy-Platform.html
  8. U.S. Food and Drug Administration. “Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments.” July 13, 2026. https://www.federalregister.gov/documents/2026/07/13/2026-14073/drug-establishment-registration-and-drug-listing-requirements-for-establishments-engaged-in
↑ Back to top